LFCR LIFECORE BIOMEDICAL, INC. \DE\
Pharmaceutical Preparations · Nasdaq · SEC CIK 1005286 · Fiscal year ends 05/25
Financial factors as of 2025-05-25 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.5%
TTM net income YoY-422.3%
TTM EPS YoY-484.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—
Margins
Gross margin31.3%
Operating margin-13.4%
Net margin-30.0%
FCF margin-10.6%
EBITDA margin-7.2%
Returns
ROE-612.1%
ROA-15.7%
ROIC (approx.)-10.7%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets80.2%
Debt / equity100.20x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.00x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue10.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2026Q12025-09-30 | 2025Q42025-05-25 | 2025Q32025-02-23 | 2025Q22024-11-24 | 2025Q12024-08-25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $25.32M | $34.17M | $23.19M | $31.11M | $36.44M | $35.15M | $32.56M | $24.70M |
| Cost of revenue | $18.50M | $22.09M | $18.73M | $23.32M | $22.46M | $25.31M | $21.48M | $19.32M |
| Gross profit | $6.83M | $12.07M | $4.46M | $7.79M | $13.98M | $9.85M | $11.08M | $5.39M |
| R&D expense | $1.42M | $1.54M | $1.22M | $1.96M | $2.10M | $2.04M | $1.92M | $2.19M |
| SG&A expense | $6.30M | $7.97M | $7.92M | $8.89M | $8.98M | $9.98M | $11.12M | $14.79M |
| Operating income | -$894,000 | $2.57M | -$4.67M | -$3.07M | $5.33M | -$9.03M | -$1.96M | -$11.58M |
| Interest expense | $8.10M | $7.75M | $7.35M | $6.38M | $5.73M | $5.59M | — | $5.38M |
| Pretax income | -$40.03M | -$6.13M | -$14.94M | -$9.66M | -$1.11M | -$14.78M | -$6.53M | -$16.25M |
| Income tax | $51,000 | $23,000 | $43,000 | $333,000 | $33,000 | -$8,000 | $43,000 | -$25,000 |
| Net income | -$40.08M | -$6.16M | -$14.98M | -$9.99M | -$1.15M | -$14.77M | -$6.57M | -$16.23M |
| EBITDA | $1.52M | $5.08M | -$2.36M | -$1.09M | $7.24M | -$6.95M | $85,000 | -$9.59M |
| EPS (basic) | -1.08 | -0.19 | -0.43 | -0.29 | -0.06 | -0.42 | -0.25 | -0.53 |
| EPS (diluted) | -1.08 | -0.19 | -0.43 | -0.29 | -0.06 | -0.42 | -0.25 | -0.53 |
| Weighted avg. shares (diluted) | 37.85M | 37.57M | 37.48M | 37.40M | 37.01M | 37.02M | 34.36M | 30.86M |
| Balance sheet | ||||||||
| Cash & equivalents | $23.04M | $17.24M | $20.80M | $18.86M | $8.27M | $5.42M | $9.46M | $5.52M |
| Receivables | — | — | — | — | — | — | $30.30M | $25.14M |
| Inventory | $27.70M | $25.48M | $28.16M | $33.80M | $32.29M | $34.60M | $39.21M | $41.64M |
| Current assets | $84.68M | $83.69M | $77.64M | $83.93M | $85.68M | $84.21M | $81.86M | $74.18M |
| PP&E, net | $122.04M | $123.71M | $125.51M | $128.57M | $129.01M | $128.22M | $150.58M | $148.76M |
| Goodwill | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M | $13.88M |
| Intangibles | — | — | — | $4.20M | $4.20M | $4.20M | $4.20M | $4.20M |
| Total assets | $228.30M | $229.50M | $225.50M | $235.20M | $239.34M | $237.69M | $255.39M | $246.82M |
| Current liabilities | $22.04M | $21.64M | $20.50M | $29.96M | $30.18M | $31.12M | $35.29M | $40.52M |
| Short-term debt | $978,000 | $970,000 | $962,000 | $947,000 | $3.44M | $930,000 | $773,000 | $773,000 |
| Long-term debt | $160.97M | $155.07M | $148.74M | $135.95M | $130.44M | $124.94M | $110.53M | $105.55M |
| Total debt | $161.94M | $156.04M | $149.70M | $136.90M | $133.87M | $125.87M | $111.30M | $106.32M |
| Total liabilities | $250.58M | $213.41M | $204.72M | $198.42M | $191.91M | $190.27M | $195.63M | $207.32M |
| Shareholders' equity | -$73.40M | -$34.09M | -$28.44M | -$10.54M | $1.34M | $2.22M | $15.45M | -$3.94M |
| Net debt | $138.91M | $138.80M | $128.91M | $118.04M | $125.61M | $120.45M | $101.85M | $100.80M |
| Shares outstanding | 37.91M | 37.70M | 37.48M | 37.47M | 37.03M | 37.03M | 36.98M | 30.90M |
| Cash flow statement | ||||||||
| Operating cash flow | $6.95M | -$2.19M | $4.70M | $1.76M | $5.35M | $1.20M | -$6.11M | -$613,000 |
| Capital expenditure | $912,000 | $513,000 | $1.12M | $1.74M | $2.10M | $5.46M | $2.47M | $3.42M |
| Free cash flow | $6.03M | -$2.70M | $3.58M | $25,000 | $3.25M | -$4.26M | -$8.58M | -$4.04M |
| Investing cash flow | -$912,000 | -$513,000 | -$1.12M | -$1.74M | -$2.10M | $1.54M | -$2.47M | -$3.42M |
| Financing cash flow | -$240,000 | -$852,000 | -$256,000 | -$1.39M | -$402,000 | -$6.78M | $12.52M | $1.09M |
| Depreciation & amortization | $2.41M | $2.52M | $2.31M | $1.98M | $1.91M | $2.08M | $2.04M | $1.99M |
| Stock-based compensation | $1.72M | $2.08M | $1.70M | $2.39M | $1.81M | $2.55M | $3.37M | $2.42M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.